||The work aimed at developing a modified release hydrogel formulation of poorly soluble drug, Gliclazide using a retardant hydrophilic polymer HPMC in two grades i.e., HPMC 15 cps and Methocel K4M. All six formulations were developed and evaluated for the in-vitro drug release up to 16hrs and compared with that of the marketed formulation. GMF VI was found to have similar release pattern proving to show controlled release following zero order release by anomalous diffusion. The similarity and Dissimilarity factors were found to be 1.12 and 93.99 respectively. Thus the formulation was found to be advantageous in reducing the dosing intervals and enhancing the patient compliance.